Early stage nonsmall cell lung cancer: Toward a risk‐adaptive paradigm in the era of biologic precision
Abstract The clinical landscape of early stage nonsmall cell lung cancer is at transformative crossroads. Driven by the widespread adoption of low‐dose computed tomography screening, the frequent detection of ground‐glass opacities, and a rising incidence among never‐smokers, the diagnostic center of gravity has shifte...